BGI SENTIS™ Colorectal Cancer (CRC) Panel

BGI SENTIS™ Colorectal Cancer (CRC) Panel


BGI is dedicated to utilizing genomics in order to advance precision medicine for cancer. BGI’s next-generation sequencing assays offer a variety of options, including targeted panels that analyze genes directly linked to specific cancers by well documented scientific research, and also much larger cancer panels designed for cancer analysis and discovery.

BGI’s cancer panels are designed to identify all four classes of actionable genomic alterations, including base substitutions, insertions and deletions, copy number alterations and selected fusions.

Colorectal cancer is the second leading cause of cancer-related mortality in the United States. BGI uses target region capture and NGS to examine 7 genes implicated in CRC targeted therapies, including those recommended in the latest NCCN guidelines.



    Patients identified with colorectal cancer

  • TA TIME:

    6 working days


    Fresh/Frozen Tumor tissue, biopsy, FFPE, DNA


    Target region capture, High-throughput sequencing

Why Choose the BGI SENTIS™ Colorectal Cancer (CRC) Panel?

  • Fast
  • Accurate
  • Affordable


Note: this test is considered a screening test, not a diagnostic test. Before making any treatment decisions, all patients should discuss their results with their healthcare provider, who can recommend confirmatory, diagnostic testing where appropriate. This testing service has not been cleared or approved by the US FDA and is not available in the USA.


Ordering the BGI SENTIS™ Colorectal Cancer (CRC) Panel is easy.

  • STEP 1

    Physician orders test

  • STEP 2

    Blood or saliva sample collected

  • STEP 3

    Sample shipped to BGI and analyzed

  • STEP 4

    Results sent to physician

Learn more

Quick Contact